Mirelle (Ethinylestradiol, Gestodene | Lactose Monohydrate)

Ethinylestradiol/Gestodene, the active ingredient in Mirelle, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus in women of reproductive age.

GNH USA supplies Mirelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance for global distribution. The company adheres to EU GMP standards and offers reliable logistics for timely delivery.

Mirelle, a combined oral contraceptive, is used within the hormonal contraceptive pathway to prevent pregnancy and manage menstrual cycle regulation. - Pregnancy prevention: inhibits ovulation and creates conditions unfavorable for fertilization. - Menstrual cycle regulation: provides more predictable bleeding patterns. - Treatment of dysmenorrhea: reduces menstrual pain associated with ovulatory cycles. - Acne management: improves acne by decreasing androgenic activity.

Mirelle may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: transient swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding. - Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Hepatic adenoma: benign liver tumor, rarely reported. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty.

Before prescribing Mirelle, clinicians should evaluate individual risk factors and contraindications. - Contraindicated in: history of thromboembolic disorders, estrogen‑dependent neoplasia, active liver disease, pregnancy, or breastfeeding. - Smoking: avoid in women over 35 who smoke heavily due to increased cardiovascular risk. - Cardiovascular risk: assess blood pressure and lipid profile prior to initiation. - Drug interactions: review concomitant medications that may reduce contraceptive efficacy, such as enzyme‑inducing agents. - Monitoring: schedule periodic evaluation of blood pressure, menstrual pattern, and signs of thrombosis. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Mirelle can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., phenytoin, carbamazepine, rifampicin): may markedly reduce contraceptive efficacy. - Protease inhibitor antiretrovirals: can increase estrogen levels, raising risk of adverse events. - St. John’s wort: herbal inducer that diminishes hormonal activity.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole): may increase plasma hormone concentrations. - Macrolide antibiotics (e.g., erythromycin): can raise hormone levels modestly. - Diuretics: may potentiate hypertension, requiring blood pressure monitoring.